Trinity Biotech
TRIB
19 hedge funds and large institutions have $5.96M invested in Trinity Biotech in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8% less capital invested
Capital invested by funds: $6.51M → $5.96M (-$550K)
71% less call options, than puts
Call options by funds: $5K | Put options by funds: $17K
86% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$87.2K |
| 2 |
AC
Aristides Capital
Louisville,
Kentucky
|
-$59.1K |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$50.1K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$48.9K |
| 5 |
LPL Financial
San Diego,
California
|
-$25.7K |
TRIB Hedge Fund Activity: Q1 2023 in Review
19 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2023, worth a combined $5.96M — down 8.4% from $6.51M a quarter earlier.
Fund positioning in TRIB was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $22.9K. The largest seller was Stonehill Capital Management, cutting an estimated $87.2K.
- 19 institutional investors held Trinity Biotech (TRIB) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $5.96M of Trinity Biotech stock for Q1 2023, down 8.4% quarter-over-quarter.
- 2 funds opened new Trinity Biotech positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q1 2023 was Citadel Advisors, an estimated $22.9K added.
- The largest Trinity Biotech seller in Q1 2023 was Stonehill Capital Management, an estimated $87.2K sold.
Based on aggregated 13F filings for Q1 2023.